Living definition
What is Tudriqev (vusolimogene oderparepvec) + Nivolumab?
Vaccines & Immunotherapy Bio, Health & Neuro
- As of
- 2026-09-30
- Revision
- 2026-10-06.1
- Method
- v1.4.0
Definition
The term, in context
AI-assisted draft · approved dataset
Tudriqev (vusolimogene oderparepvec) is an oncolytic herpes simplex virus therapy engineered to selectively replicate within tumor cells, causing direct lysis while expressing an immune-stimulating transgene intended to prime a broader anti-tumor immune response; it is designed for use alongside nivolumab, a PD-1 immune checkpoint inhibitor monoclonal antibody, combining direct tumor cell destruction with checkpoint blockade as a combination approach for treating melanoma.
Live readiness status
Status as of the current dateline
AI-assisted assembly · derived results
As of 2026-09-30, verified readiness is 45 (claimed 55, reported 45, gap 10) — Strong evidence strength; current signals suggest An approved option for its defined melanoma indication, with confirmatory benefit still pending.
The readiness fact belongs to the canonical Readiness Verdict for Tudriqev (vusolimogene oderparepvec) + Nivolumab.
Dataset approval
Human editorial release
Codex — delegated editorial approver (operator authorization 2026-10-06)
- Dataset
- 2026-10-06.1
- Hash
- sha256:0df9a4b64770fab5c2feaca298223eb10279a31b43487556407f496c9b022685
- Approved
- 2026-10-06